Aziyo Biologics, Inc

Aziyo Biologics, Inc. operates as a biotechnology company which focuses on regenerative medicine in areas such as cardiology, orthopedics and other medical specialties. It offers cardiac device envelope, vascular surgery, cardiothoracic repair, orthopedics and spine, sports medicine, dermal, and wound care. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Elutia, Inc. operates as a biotechnology company. It develops biologic products to improve compatibility between medical devices and the patients who need them. The firm operates through the following segments: Device Protection, Women’s Health, Orthobiologics and Cardiovascular. The Device Protection segment includes biological envelope that remodels into systematically connected, vascularized tissue for the long-term pocket protection of certain cardiac and neurostimulator implantable electronic vehicles. The Women’s Health segment includes pre-hydrated, human acellular dermal matrix, or HADM, that is designed to enable rapid integration, cellular repopulation and rapid revascularization at the surgical site. The Orthobiologics segment includes a variety of viable matrices, produced with a proprietary process that is designed to protect and preserve native bone cells and reduce programmable cell death, for use in bone repair and fusion procedures. The Cardiovascular segment includes a portfolio of extracellular matrices that retain the natural composition of collagen, growth factors and proteins for use in vascular and cardiac repair and pericardial closure. The company was founded by Kevin L. Rakin and Charles Randal Mills on August 6, 2015 and is headquartered in Silver Spring, MD.

SILVER SPRING, Md., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its fourth quarter and full year 2021 earnings results after market close on Thursday, March 3, 2022. Management will host a conference call to review the Company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

Aziyo Biologics to Report Fourth Quarter and Full Year 2021 Financial Results on Thursday, March 3, 2022

Aziyo Biologics, Inc. (AZYO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Aziyo Biologics, Inc. (AZYO) Rating Upgrade to Buy

Here is how Aziyo Biologics, Inc. (AZYO) and Doximity (DOCS) have performed compared to their sector so far this year.

Has Aziyo Biologics, Inc. (AZYO) Outpaced Other Medical Stocks This Year?

The consensus price target hints at a 123.3% upside potential for Aziyo Biologics, Inc. (AZYO). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 123% Upside in Aziyo Biologics, Inc. (AZYO): Can the Stock Really Move This High?

SILVER SPRING, Md., Dec. 27, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that members of management will present at the upcoming H.C. Wainwright Bioconnect Virtual Conference.

Aziyo Biologics to Present at the H.C. Wainwright Bioconnect Virtual Conference

SILVER SPRING, Md., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the “Company”), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the closing of the previously announced private investment in public equity (PIPE) financing. The Company received aggregate gross proceeds of approximately $14.0 million, before deducting offering expenses. The PIPE financing was led by a fund affiliated with Birchview Capital, with participation from existing investors including funds affiliated with Deerfield Management Company and HighCape Capital.

Aziyo Biologics Announces Closing of $14.0 Million Private Placement

SILVER SPRING, Md., Dec. 06, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (the “Company”) today announced that it has entered into a definitive agreement to sell securities in a private placement that is expected to result in gross proceeds to the Company of approximately $14.0 million, before deducting offering expenses.

Aziyo Biologics Announces $14.0 Million Private Placement

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q3 2021 Results - Earnings Call Transcript

Aziyo Biologics, Inc. (AZYO) delivered earnings and revenue surprises of -32.79% and -0.47%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Aziyo Biologics, Inc. (AZYO) Reports Q3 Loss, Misses Revenue Estimates

SILVER SPRING, Md., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and nine months ended September 30, 2021.

Aziyo Biologics Reports Third Quarter 2021 Financial Results

Aziyo Biologics, Inc. (AZYO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Will Aziyo Biologics, Inc. (AZYO) Report Negative Earnings Next Week? What You Should Know

SILVER SPRING, Md., Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it was informed by Medtronic that, after conducting a thorough review of customer and patient needs, Medtronic has made the decision to cease distribution of Cellular Bone Matrix (CBM) products. As a result of this decision, the two companies are working toward a mutual termination of their FiberCel distribution agreement.

Aziyo Biologics Provides Business Update and Preliminary Third Quarter 2021 Revenue Results and Announces Timing for Third Quarter 2021 Financial Results

SILVER SPRING, Md., Sept. 15, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming 2021 Cantor Global Healthcare Conference.

Aziyo Biologics to Participate in the 2021 Cantor Global Healthcare Conference

SILVER SPRING, Md., Aug. 31, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the appointment of Peter G. Edwards as General Counsel.

Aziyo Biologics Appoints Peter G. Edwards as General Counsel

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q2 2021 Results - Earnings Call Transcript

SILVER SPRING, Md., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three and six months ended June 30, 2021.

Aziyo Biologics Reports Second Quarter 2021 Financial Results

SILVER SPRING, Md., July 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its second quarter earnings results after market close on Monday, August 9, 2021. Management will host a conference call to review the company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

Aziyo Biologics to Report Second Quarter 2021 Financial Results on Monday, August 9, 2021

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q1 2021 Results - Earnings Call Transcript

SILVER SPRING, Md., May 04, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the three months ended March 31, 2021.

Aziyo Biologics Reports First Quarter 2021 Financial Results and Increases 2021 Revenue Guidance

SILVER SPRING, Md., April 28, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, announced today the initiation of a multi-center observational study to provide insight into the clinical profiles, procedural details and post-implant outcomes in patients receiving Aziyo's CanGaroo® Envelope or no envelope during initial (de novo) cardiac implantable electronic device (CIED) placement.

Aziyo Biologics Announces Initiation of De Novo CanGaroo Clinical Study

SILVER SPRING, Md., April 26, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Truist Securities Life Sciences Summit.

Aziyo Biologics to Participate in the Truist Securities Life Sciences Summit

SILVER SPRING, Md., April 20, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced that it plans to release its first quarter earnings results after market close on Tuesday, May 4, 2021. Management will host a conference call to review the company's financial performance starting at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time on the same day. The conference call will be concurrently webcast.

Aziyo Biologics to Report First Quarter 2021 Financial Results on Tuesday, May 4, 2021

Aziyo Biologics, Inc. (AZYO) CEO Ronald Lloyd on Q4 2020 Results - Earnings Call Transcript

SILVER SPRING, Md., March 01, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today reported financial results for the fourth quarter and full year ended December 31, 2020.

Aziyo Biologics Reports Fourth Quarter and Full Year 2020 Financial Results

SILVER SPRING, Md., Feb. 18, 2021 (GLOBE NEWSWIRE) -- Aziyo Biologics, Inc. (Nasdaq: AZYO), a commercial-stage regenerative medicine company focused on creating the next generation of differentiated products and improving outcomes in patients undergoing surgery, today announced the Company will participate in the upcoming Cowen 41st Annual Health Care Conference.

News for Aziyo Biologics, Inc Stock (AZYO)